Alvarez Carlos A, Mortensen Eric M, Makris Una E, Berlowitz Dan R, Copeland Laurel A, Good Chester B, Amuan Megan E, Pugh Mary Jo V
Pharmacy Practice Department, Texas Tech University Health Sciences Center, Forest Park Rd, Dallas, TX, USA.
BMC Geriatr. 2015 Jan 27;15:2. doi: 10.1186/1471-2318-15-2.
High-risk medication exposure in the elderly is common and associated with increased mortality, hospitalizations, and emergency department (ED) visits. Skeletal muscle relaxants and antihistamines are high-risk medications commonly prescribed in elderly patients. The objective of this study was to determine the association between skeletal muscle relaxants or antihistamines and mortality, hospitalizations, and emergency department visits.
This study used a new-user, retrospective cohort design using national Veteran Affairs (VA) data from 128 hospitals. Veterans ≥65 years of age on October 1, 2005 who received VA inpatient/outpatient care at least once in each of fiscal year (FY) 2005 and FY 2006 were included. Exposure to skeletal muscle relaxants and antihistamines was defined by the National Committee for Quality Assurance Healthcare Effectiveness Data and Information Set measures for high-risk medications in the elderly. Primary outcomes identified within one year of exposure were death, ED visit, or hospitalization; ED visits or hospitalizations due to falls and fracture were also assessed. Propensity score matching (1 to 1 match) was used to balance covariates between exposed patients and non-exposed patients.
In this cohort of 1,807,404 patients 55,566 patients were included in the propensity-matched cohort for skeletal muscle relaxants and 60,058 patients were included in the propensity-matched cohort for anti-histamines. Mortality was lower in skeletal muscle relaxants-exposed patients (adjusted odds ratio [AOR] 0.87, 95% CI 0.81-0.94), but risk of emergency care (AOR 2.25, 95% CI 2.16-2.33) and hospitalization (AOR 1.56, 95% CI 1.48-1.65) was higher for patients prescribed skeletal muscle relaxants. Similar findings were observed for emergency and hospital care for falls or fractures. Mortality (AOR 1.93, 95% CI 1.82-2.04), ED visits (AOR 2.35, 95% CI 2.27-2.43), and hospitalizations (AOR 2.21, 95% CI 2.11-2.32) were higher in the antihistamine-exposed group, with similar findings for falls and fractures outcomes.
Skeletal muscle relaxants and antihistamines are associated with an increased risk of ED visits and hospitalizations in elderly patients. Antihistamines were also associated with an increased risk of death, further validating the classification of these drug classes as "high risk".
老年人高风险药物暴露很常见,且与死亡率增加、住院率增加以及急诊就诊次数增加相关。骨骼肌松弛剂和抗组胺药是老年患者常用的高风险药物。本研究的目的是确定骨骼肌松弛剂或抗组胺药与死亡率、住院率及急诊就诊次数之间的关联。
本研究采用新使用者回顾性队列设计,使用来自128家医院的国家退伍军人事务部(VA)数据。纳入2005年10月1日年龄≥65岁、在2005财年和2006财年每年至少接受一次VA住院/门诊护理的退伍军人。根据国家质量保证委员会医疗保健有效性数据和信息集对老年人高风险药物的衡量标准来定义对骨骼肌松弛剂和抗组胺药的暴露。暴露后一年内确定的主要结局为死亡、急诊就诊或住院;还评估了因跌倒和骨折导致的急诊就诊或住院情况。采用倾向评分匹配(1:1匹配)来平衡暴露患者和未暴露患者之间的协变量。
在这1,807,404名患者的队列中,55,566名患者被纳入骨骼肌松弛剂倾向匹配队列,60,058名患者被纳入抗组胺药倾向匹配队列。暴露于骨骼肌松弛剂的患者死亡率较低(调整优势比[AOR]0.87,95%置信区间0.81 - 0.94),但开具骨骼肌松弛剂的患者接受急诊护理的风险(AOR 2.25,95%置信区间2.16 - 2.33)和住院风险(AOR 1.56,95%置信区间1.48 - 1.65)较高。对于跌倒或骨折导致的急诊和住院护理也观察到类似结果。抗组胺药暴露组的死亡率(AOR 1.93,95%置信区间1.82 - 2.04)、急诊就诊次数(AOR 2.35,95%置信区间2.27 - 2.43)和住院率(AOR 2.21,95%置信区间2.11 - 2.32)较高,跌倒和骨折结局也有类似发现。
骨骼肌松弛剂和抗组胺药与老年患者急诊就诊和住院风险增加相关。抗组胺药还与死亡风险增加相关,进一步证实了将这些药物类别归类为“高风险”的合理性。